Back to Stakeholders
Categories

1 domain / 2 areas / 2 specializations

Research, Drug Development & Manufacturing
Academic & Non-Profit ResearchIndependent Academic Research GroupsSpecialized Academic Departments and Institutes
Research, Drug Development & Manufacturing

Johns Hopkins Center for Psychedelic and Consciousness Research

1 Paper

A research center within Johns Hopkins University (School of Medicine) that conducts scientific studies on psychedelic compounds, their effects on brain function and consciousness, and their therapeutic potential for mental health conditions.

Academic Research

1 papers

Published Papers

1

Trial Involvement

0

Distinct Focus Topics

0

Latest Publication

May 2, 2026

Recent Papers

Government funding received

3 grants

NCCIH R33AT012317 — Psilocybin and affective function in chronic low-back pain + depression

2023–2027

National Center for Complementary and Integrative Health (NCCIH)$1,518,560
PsilocybinChronic Pain

Phase 1 R33 trial: single high-dose psilocybin (25 mg) vs methylphenidate (40 mg active control) in patients with co-morbid chronic low-back pain and depression. Mechanistic / affective-outcomes focus. Contact PI: David Bryce Yaden (Hopkins CPCR), multi-PI: Patrick Finan. Funded by the NIH National Center for Complementary and Integrative Health. Amount shown is total awarded to date across FY2023-FY2025 per NIH RePORTER ($479K + $528K + $512K = $1.52M); project runs through April 2027.

Source

NIDA U01DA052174 — Multisite psilocybin trial for smoking cessation

2021–2024

National Institute on Drug Abuse (NIDA)$4,000,000
PsilocybinTobacco/Nicotine Use Disorder (TUD)

First NIH grant in over 50 years to directly investigate the therapeutic effects of a classic psychedelic. Multisite study with Hopkins as lead, plus University of Alabama at Birmingham and New York University as subaward sites. PI: Matthew W. Johnson. Award U01DA052174.

Source

NIDA R01 DA042103 — Psilocybin facilitation of smoking cessation

2017–2022

National Institute on Drug Abuse (NIDA)$3,960,000
PsilocybinTobacco/Nicotine Use Disorder (TUD)

PI: Matthew W. Johnson (Center for Psychedelic and Consciousness Research, Johns Hopkins University). Five-year R01 project funding controlled trials of psilocybin for tobacco-use disorder. Total funding figure is the cumulative project total per NIH RePORTER.

Source

Quick Facts

Website
Visit

Research Papers

1
Paywallindividual

5-HT1A receptor blockade potentiates the subjective effects of DMT

This double-blind, randomised, placebo-controlled within-subjects study (n=12) found that blocking the 5-HT1A receptor with 30 mg oral pindolol before a sub-hallucinogenic intravenous dose of DMT (7 mg/70kg) intensified the subjective effects with a moderate effect size, suggesting the 5-HT1A receptor contributes to how psychedelics produce their subjective effects.

Published
Journal
Journal of Psychopharmacology
Authors
Zahid, Z., Strassman, R. J., Qualls, C. R., Nayak, S. M.